A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma

Orešković, Slavko; Babić, Damir; Kalafatić, Držislav; Barišić, Dajana; Beketić-Orešković, Lidija

doi:10.1016/j.ygyno.2003.12.038

Cited by 57 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, the differences in PR status observed among the three groups may be relevant as prognostic factors, when considering literature data showing that PR status may have greater significance for predicting survival than the ERα status in patients with histologic grade 3 [21]. Again, in term of prognosis, HGECs appear to place themselves in an intermediate position between…”

Section: Discussionmentioning

confidence: 94%

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study

et al. 2010

View full text Add to dashboard Cite

This study was aimed at determining whether high-grade endometrioid carcinomas (grade 3 International Federation of Gynecology and Obstetrics) might overlap, at least partially, non-endometrioid carcinomas (type II). To this end, a panel of clinical-pathological and immunohistochemical parameters was evaluated in three different populations: low-grade endometrioid carcinomas (LGECs; n = 57), high-grade endometrioid carcinomas (HGECs; n = 26), and non-endometrioid carcinomas (NECs; n = 30). Besides morphological appearance, HGECs appeared similar to LGECs in p53 immunostaining profile; features different from LGECs included a higher local aggressiveness, a higher invasion of lymph-vascular spaces, a lower expression of ERalpha and PR, and a higher proliferative index. HGECs were similar to NECs for local aggressiveness, invasion rate of lymph-vascular spaces, lymph node metastasis incidence, and proliferative index. HGECs, however, showed a lower rate of extra-nodal metastases, a lower incidence of p53 overexpression, and a higher positivity for ERalpha and PR. In conclusion, results from this study show that HGECs exhibit overlapping morphological and immunohistochemical features of both type I and type II endometrial carcinomas. Further research is needed to clarify the clinical value of this observation.

show abstract

Section: Discussionmentioning

confidence: 94%

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Still, relatively poor correlation between curettage and hysterectomy findings has motivated the search for improved measures to define high and low-risk patients (29). Markers for hormone receptor and p53 status in tumor based on investigation of curettage specimens have consistently shown to add prognostic information (24,(30)(31)(32). We have in an earlier, smaller, retrospective singlecenter study (9) investigated Stathmin in hysterectomy specimens.…”

Section: Discussionmentioning

confidence: 99%

Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer

Trovik

Wik²,

Stefansson³

et al. 2011

Clinical Cancer Research

114

112

View full text Add to dashboard Cite

Purpose: Overexpression of the oncogen Stathmin has been linked to aggressive endometrial carcinoma and a potential for PI3Kinase inhibitors in this disease. We wanted to validate the prognostic value of Stathmin expression in a large prospective multicenter setting. As lymph node sampling is part of current surgical staging, we also aimed to test if Stathmin expression in endometrial curettage specimens could predict lymph node metastasis.Experimental Design: A total of 1,076 endometrial cancer patients have been recruited from 10 centers to investigate the biological tumor marker Stathmin in relation to clinicopathologic variables, including lymph node status and survival. Stathmin immunohistochemical staining was carried out in 477 hysterectomy and 818 curettage specimens.Results: Seventy-one percent of the patients (n ¼ 763) were subjected to lymph node sampling, of which 12% had metastatic nodes (n ¼ 94). Overexpression of Stathmin was detected in 37% (302 of 818) of the curettage and in 18% (84 of 477) of the hysterectomy specimens investigated. Stathmin overexpression in curettage and hysterectomy specimens were highly correlated and significantly associated with nonendometrioid histology, high grade, and aneuploidy. Stathmin analysis in preoperative curettage samples significantly correlated with, and was an independent predictor of, lymph node metastases. High Stathmin expression was associated with poor disease-specific survival (P 0.002) both in curettage and hysterectomy specimens.Conclusions: Stathmin immunohistochemical staining identifies endometrial carcinomas with lymph node metastases and poor survival. The value, as a predictive marker for response to PI3Kinase inhibition and as a tool to stratify patients for lymph node sampling in endometrial carcinomas, remains to be determined. Clin Cancer Res; 17(10); 3368-77. Ó2011 AACR.

show abstract

“…This unusual situation might reflect that the current used diagnostic technology is quite insufficient to identify endometrial cancer patients with poor prognosis. Therefore, immunohistochemistry of different specific markers might be an interesting alternative to select high risk patients leading to a more patient specific risk profile and treatment (22,23,31,32).…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance and clinical importance of estrogen receptor α and β in human endometrioid adenocarcinomas

Mylonas¹

2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Human endometrial cancer expresses both the known estrogen receptors (ER-· and ER-ß). The significance of the relative expression of both ER subtypes in endometrial adenocarcinomas remains to be clarified and the usefulness of the determination of the receptor status in endometrial cancer patients is still controversially discussed. Therefore, the aims of this study were the evaluation of the expression patterns of ER-· and ER-ß with the characterization of the prognostic significance in uterine endometrioid adenocarcinomas. Pathological and surgical records of 214 patients who were diagnosed with an endometrioid adenocarcinoma without other histological types (including mucinous, mixed, squamous or villoglandular differentiation) were reviewed for both estrogen receptors. The expression of both estrogen receptors was demonstrated in malignant endometrioid adenocarcinomas. ER-· was associated with histological differentiation, while ER-ß demonstrated an association with ovarial invasion. The loss of receptor positivity for ER-· resulted in a poorer causespecific survival in endometrial cancer patients, while ER-ß did not affect survival. Interestingly, metastatic patients who expressed ER-· or ER-ß had a better survival outcome than estrogen receptor negative patients. Moreover, when tumor samples of affected patients expressed ER-·, they had a better cause-specific survival compared to negative findings regarding both estrogen receptors. However, ER-· and ER-ß were not independent factors with survival in endometrial adenocarcinoma patients. Therefore, the analysis of both estrogen receptors might be used as a marker to identify highrisk patients only in a subset of patients with endometrioid adenocarcinoma.

show abstract

A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma

Cited by 57 publications

References 35 publications

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study

Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer

Prognostic significance and clinical importance of estrogen receptor α and β in human endometrioid adenocarcinomas

Contact Info

Product

Resources

About